97 related articles for article (PubMed ID: 24685913)
21. Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer.
dos Reis ST; Villanova FE; Andrade PM; Pontes J; de Sousa-Canavez JM; Sañudo A; Antunes AA; Dall'oglio MF; Srougi M; Moreira Leite KR
Urol Oncol; 2010; 28(6):624-7. PubMed ID: 19117773
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S-transferase T1 and M1 polymorphisms are associated with lung cancer risk in a gender-specific manner.
Pan C; Zhu G; Yan Z; Zhou Y; Liu Z
Oncol Res Treat; 2014; 37(4):164-9. PubMed ID: 24732639
[TBL] [Abstract][Full Text] [Related]
24. Assessment of association between common variants at 17q12 and prostate cancer risk-evidence from Serbian population and meta--analysis.
Nikolić ZZ; Branković AS; Savić-Pavićević DL; Preković SM; Vukotić VD; Cerović SJ; Filipović NN; Tomović SM; Romac SP; Brajušković GN
Clin Transl Sci; 2014 Aug; 7(4):307-13. PubMed ID: 24422606
[TBL] [Abstract][Full Text] [Related]
25. 8q24 rs4242382 polymorphism is a risk factor for prostate cancer among multi-ethnic populations: evidence from clinical detection in China and a meta-analysis.
Zhao CX; Liu M; Xu Y; Yang K; Wei D; Shi XH; Yang F; Zhang YG; Wang X; Liang SY; Zhao F; Zhang YR; Wang NN; Chen X; Sun L; Zhu XQ; Yuan HP; Zhu L; Yang YG; Tang L; Jiao HY; Huo ZH; Wang JY; Yang Z
Asian Pac J Cancer Prev; 2014; 15(19):8311-7. PubMed ID: 25339022
[TBL] [Abstract][Full Text] [Related]
26. ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.
Xu B; Tong N; Li JM; Zhang ZD; Wu HF
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):270-7. PubMed ID: 20231859
[TBL] [Abstract][Full Text] [Related]
27. Association between VHL single nucleotide polymorphism (rs779805) and the susceptibility to prostate cancer in Chinese.
Chen J; Wu Y; Shao P; Cao Q; Qin C; Li P; Ding Q; Zhu J; Wang M; Zhang Z; Li J; Yin C
DNA Cell Biol; 2012 May; 31(5):790-6. PubMed ID: 22084938
[TBL] [Abstract][Full Text] [Related]
28. rs10505474 and rs7837328 at 8q24 cumulatively confer risk of prostate cancer in Northern Han Chinese.
Zhang LL; Sun L; Zhu XQ; Xu Y; Yang K; Yang F; Yang YG; Chen GQ; Fu JC; Zheng CG; Li Y; Mu XQ; Shi XH; Zhao F; Wang F; Yang Z; Wang BY
Asian Pac J Cancer Prev; 2014; 15(7):3129-32. PubMed ID: 24815458
[TBL] [Abstract][Full Text] [Related]
29. hOGG1 rs1052133 Polymorphism and Prostate Cancer Risk: A Chinese Case-Control Study and Meta-Analysis.
Xu H; Zhang M; Hao Z; Liang C
Med Sci Monit; 2022 Oct; 28():e938012. PubMed ID: 36310366
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of genetic biomarkers in clinical progression of prostate cancer.
Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Saiz M; Carmona-Saez P; Alvarez JC; Pascual-Geler M; Lorente JA; Cozar JM
Exp Mol Med; 2015 Aug; 47(8):e176. PubMed ID: 26251261
[TBL] [Abstract][Full Text] [Related]
31. MSMB gene variant alters the association between prostate cancer and number of sexual partners.
Stott-Miller M; Wright JL; Stanford JL
Prostate; 2013 Dec; 73(16):1803-9. PubMed ID: 24037734
[TBL] [Abstract][Full Text] [Related]
32. [Association between the myeloperoxidase gene polymorphisms and the susceptibility to prostate cancer: a case-control study in a Chinese population].
Ding G; Liu F; Feng C; Xu J; Ding Q
Actas Urol Esp; 2013 Feb; 37(2):79-82. PubMed ID: 23260186
[TBL] [Abstract][Full Text] [Related]
33. A Systematic Review and Meta-Analysis of Three Gene Variants Association with Risk of Prostate Cancer: An Update.
Chen Y; Zhong H; Gao JG; Tang JE; Wang R
Urol J; 2015 Jul; 12(3):2138-47. PubMed ID: 26135929
[TBL] [Abstract][Full Text] [Related]
34. Lack of Association between MDR1 G2677T/A Polymorphism and Leukemia Risk: An Updated Meta-Analysis.
Ma L; Yang H; Ruan L
Oncol Res Treat; 2015; 38(7-8):383-4. PubMed ID: 26278584
[No Abstract] [Full Text] [Related]
35. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.
Kim ST; Cheng Y; Hsu FC; Jin T; Kader AK; Zheng SL; Isaacs WB; Xu J; Sun J
Prostate; 2010 Dec; 70(16):1729-38. PubMed ID: 20564319
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer risk-associated genetic markers and their potential clinical utility.
Xu J; Sun J; Zheng SL
Asian J Androl; 2013 May; 15(3):314-22. PubMed ID: 23564047
[TBL] [Abstract][Full Text] [Related]
37. CDKN1B Val 109 Gly variant is not related to risk of prostate cancer.
Zhu L; Wang J; Yue C; Yuan W; Zhang W; Shi L; Mi Y; Wu X; Zhang LF; Zuo L
J Cell Biochem; 2019 Oct; 120(10):18346-18356. PubMed ID: 31257659
[TBL] [Abstract][Full Text] [Related]
38. Clinical validity and utility of genetic risk scores in prostate cancer.
Helfand BT; Kearns J; Conran C; Xu J
Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
[TBL] [Abstract][Full Text] [Related]
39. Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer.
Yan Y; Xu J; Xu B; Wen Q; Zhou J; Zhang L; Zuo L; Lv G; Shi Y
J Clin Lab Anal; 2020 Sep; 34(9):e23403. PubMed ID: 32488882
[TBL] [Abstract][Full Text] [Related]
40. Estimation of absolute risk for prostate cancer using genetic markers and family history.
Xu J; Sun J; Kader AK; Lindström S; Wiklund F; Hsu FC; Johansson JE; Zheng SL; Thomas G; Hayes RB; Kraft P; Hunter DJ; Chanock SJ; Isaacs WB; Grönberg H
Prostate; 2009 Oct; 69(14):1565-72. PubMed ID: 19562736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
